MGX - NASDAQ
Metagenomi, Inc. Common Stock
$1.35
+3.8%Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
At a Glance
Live SnapshotMetagenomi, Inc. Common Stock Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Metagenomi, Inc. Common Stock Balance Sheet
MGX • NASDAQ
| Metagenomi, Inc. Common Stock Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
ASSETS | |||||
CURRENT ASSETS | |||||
41.7M | 27.4M | 140.6M | 184.4M | 39.3M | |
119.1M | 220.9M | 130.6M | 177.7M | 68.9M | |
160.8M | 248.3M | 271.2M | 362.1M | 108.2M | |
305K | 1.3M | 2.5M | 1.3M | 490K | |
305K | 1.3M | 2.5M | 0.0 | 490K | |
0.0 | 0.0 | 0.0 | 1.3M | 0.0 | |
0.0 | 0.0 | 0.0 | 685K | 0.0 | |
4.4M | 8.4M | 4.6M | 2.8M | 272K | |
165.5M | 258M | 278.3M | 366.9M | 108.9M | |
NON-CURRENT ASSETS | |||||
47.4M | 57.7M | 65.2M | 33.3M | 22.1M | |
2.2M | 3.4M | 15.9M | 7.8M | 6.4M | |
6M | 5.5M | 5.5M | 6.5M | 4.5M | |
55.6M | 66.6M | 86.6M | 47.6M | 33.1M | |
221.1M | 324.6M | 364.8M | 414.5M | 142M | |
LIABILITIES | |||||
CURRENT LIABILITIES | |||||
1.5M | 533K | 5.1M | 3.5M | 1.4M | |
1.5M | 533K | 1.8M | 2M | 1.4M | |
0.0 | 0.0 | 3.3M | 1.5M | 0.0 | |
0.0 | 3.1M | 7.3M | 4M | 1.3M | |
6M | 0.0 | 3.4M | 0.0 | 0.0 | |
0.0 | 5.6M | 0.0 | 1.5M | 687K | |
0.0 | 0.0 | 3.3M | 1.5M | 0.0 | |
8.7M | 22.8M | 48.9M | 33.9M | 16M | |
6.7M | 5.3M | 4.2M | 5.6M | 5.8M | |
22.9M | 37.3M | 68.9M | 48.5M | 25.2M | |
NON-CURRENT LIABILITIES | |||||
0.0 | 0.0 | 0.0 | 0.0 | 30.3M | |
3M | 10.2M | 30.9M | 76.2M | 23.7M | |
2M | 2M | 5.1M | 347.1M | 77.4M | |
39.6M | 52.4M | 80.8M | 440.4M | 149.4M | |
34.6M | 45.8M | 44.8M | 18.6M | 18.7M | |
62.5M | 89.7M | 149.7M | 488.9M | 174.5M | |
SHAREHOLDERS' EQUITY | |||||
0.0 | 0.0 | 350.8M | 0.0 | 0.0 | |
4K | 4K | 26K | 2.5M | 573K | |
469.2M | 457.1M | 0.0 | 0.0 | 0.0 | |
-310.9M | -223M | -144.9M | -76.7M | -33.1M | |
260K | 709K | 9.3M | -274K | -21K | |
158.6M | 234.9M | 215.2M | -74.4M | -32.5M | |
158.6M | 234.9M | 215.2M | -74.4M | -32.5M | |
SUMMARY | |||||
221.1M | 324.6M | 364.8M | 414.5M | 142M | |
121.2M | 224.4M | 146.5M | 185.5M | 75.3M | |
40.7M | 45.8M | 48.2M | 18.6M | 48.9M | |
-1.1M | 18.4M | -92.4M | -165.9M | 9.6M | |
37,533,136 | 37,533,136 | 37,533,136 | 37,533,136 | 37,533,136 |
SEC Filings
MGX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 11, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 27, 2026 | April 21, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 05, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 12, 2025 | November 11, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 01, 2025 | September 29, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 12, 2025 | June 30, 2025 | 2025 |
Related Guides
Continue your MGX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.